Novartis, Mylan Spar Over Breast Cancer Treatment

Law360, New York (June 28, 2006, 12:00 AM EDT) -- Drug makers Novartis Pharmaceuticals and Mylan Pharmaceuticals will meet in court over the patents for breast cancer treatment Femara, after an Abbreviated New Drug Application prompted Novartis to slap the generics maker with a lawsuit.

In the suit, filed in the U.S. District Court for the District of New Jersey, Novartis asserts a patent for letrozole, the active ingredient in Femara, a treatment for breast cancer in postmenopausal women.

The patent covers the chemical compound for letrozole, as well as “methods of inhibiting aromatase activity and...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.